DEF: IRADIMED Corporation Announces 2025 Annual Meeting of Stockholders

IRADIMED Corporation has scheduled its 2025 Annual Meeting of Stockholders for June 19, 2025, to elect directors, ratify the appointment of its independent accounting firm, and conduct an advisory vote on executive compensation.

Summary

• IRADIMED Corporation will hold its 2025 Annual Meeting of Stockholders on June 19, 2025, at 10:00 a.m. local time at the company's offices in Winter Springs, Florida.
• Stockholders of record as of April 21, 2025, are entitled to vote at the meeting.
• The agenda includes the election of five directors, ratification of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2025, and a non-binding advisory vote on the fiscal 2024 compensation of the company's named executive officers.
• The Board of Directors recommends voting FOR all director nominees and FOR Proposals 2 and 3.
• As of the record date, there were 12,715,109 shares of Common Stock outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a generally positive outlook conveyed through the Board's recommendations and management's expressions of gratitude. The financial highlights for 2024 are presented positively, contributing to a moderately optimistic sentiment.

Positives

• The Board of Directors is recommending a vote FOR all proposals, indicating confidence in the company's direction and performance.
• The company is providing multiple methods for stockholders to vote, including internet, telephone, and mail, to ensure maximum participation.
• The Audit Committee has pre-approved all auditing services and permitted non-audit services to be performed by the independent registered public accounting firm.

Future Outlook

The company is continuing construction of a new corporate office and manufacturing facility in Orange County, Florida, to accommodate increased operations and anticipated growth, with an estimated total cost of $20 million and completion expected in 2025.

Management Comments

• Roger Susi, Chairman of the Board, President and Chief Executive Officer, expresses gratitude for continued stockholder support and anticipates the Annual Meeting.

Industry Context

The document does not explicitly compare IRADIMED's performance to specific industry benchmarks or competitors, but it does mention that the company's compensation practices are designed to be competitive within the market for executive talent.

Management Changes

Corporate Governance

Related Party Transactions

• The company leases its manufacturing and headquarters facility from Susi, LLC, an entity controlled by Roger Susi, the Chairman of the Board, President, and Chief Executive Officer.
• For the year ended December 31, 2024, the company paid Susi, LLC $518,348 related to this lease.
• The lease amendment extends the lease on a month-to-month basis for up to six months after May 31, 2025.

Stakeholder Impact

• The election of directors and the advisory vote on executive compensation directly impact shareholders.
• The ratification of the independent auditor ensures the integrity of financial reporting, benefiting shareholders and other stakeholders.
• The company's ongoing capacity expansion aims to support continued growth, potentially benefiting employees, customers, and suppliers.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on June 19, 2025.
• The company will continue construction of its new corporate office and manufacturing facility, expected to be completed in 2025.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Board of Directors, Director Election, Executive Compensation, RSM US LLP, Independent Auditor, Corporate Governance, IRADIMED